502O Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial

Autor: Tougeron, D., Emile, J-F., Bodere, A., Barbier, E., Bez, J., Dourthe, L.M., Perrier, H., Corbinais, S., Le Brun-Ly, V., Bideau, K., Chibaudel, B., Akouz, F. Khemissa, Hartwig, J., Laly, M., Lievre, A., Toullec, C., Lomenie, N., Laurent-Puig, P., Lepage, C., Taieb, J.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S428-S428

572P Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial

Autor: Aparicio, T., Etienne, P-L., Bouche, O., Barbier, E., Hiret, S., Ammarguellat, H., Desgrippes, R., Martin, J., Meyer, V. Guerin, Le Brun-Ly, V., Ben Abdelghani, M., Falandry, C., Turpin, J., Rinaldi, Y., Desrame, J., Darrius, R., Villing, A-L., Furtos, C.I., Lepage, C., Mineur, L.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S465-S466

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

Autor: Aparicio, T., Bouché, O., Etienne, P. L., Barbier, E., Mineur, L., Desgrippes, R., Guerin-Meyer, V., Hocine, F., Martin, J., Le Brun-Ly, V., Cretin, J., Desramé, J., Rinaldi, Y., Cany, L., Falandry, C., Lefevre, L. B., Marous, M., Terrebonne, E., Mosser, L., Turpin, J., Turpin, A., Bauguion, L., Reichling, C., Eynde, M., Carola, E., Hiret, S.

Publikováno v: Digestive and Liver Disease, Vol. /, no./, p. / (2022)
Digestive and Liver Disease
Digestive and Liver Disease, 2022, pp.S1590-8658(22)00662-4. ⟨10.1016/j.dld.2022.08.036⟩

International audience; BACKGROUND: Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection, but this improvement was not demonstrated in olde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6e5a5ace431d56ccfe51565a387f0e2
https://pubmed.ncbi.nlm.nih.gov/36115817

1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study

Autor: Pautier, P., Italiano, A., Piperno-Neumann, S., Chevreau, C.M., Penel, N., Firmin, N., Rouquette, P. Boudou, Bertucci, F., Le Brun-Ly, V., Ray-Coquard, I.L., Kalbacher, E., Bompas, E., Collard, O., Isambert, N., Guillemet, C., Rios, M., Le Cesne, A., Archambaud, B., Duffaud, F.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S1030-S1030

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.